|
|
Travere Therapeutics Inc (TVTX) |
|
Price: $8.9400
$-0.04 
-0.445%
|
| Day's High:
| $9.28
| Week Perf:
| 11.06 %
|
| Day's Low: |
$ 8.94 |
30 Day Perf: |
-32.22 % |
| Volume (M): |
1,090 |
52 Wk High: |
$ 26.55 |
| Volume (M$): |
$ 9,744 |
52 Wk Avg: |
$18.65 |
| Open: |
$9.08 |
52 Wk Low: |
$7.00 |
|
|
| Market Capitalization (Millions $) |
679 |
| Shares
Outstanding (Millions) |
76 |
| Employees |
500 |
| Revenues (TTM) (Millions $) |
226 |
| Net Income (TTM) (Millions $) |
-307 |
| Cash Flow (TTM) (Millions $) |
-5 |
| Capital Exp. (TTM) (Millions $) |
31 |
Travere Therapeutics Inc
Travere Therapeutics Inc. is a pharmaceutical company that specializes in developing and commercializing treatments for rare and complex diseases. The company was founded in 1988 as Raptor Pharmaceuticals Corp. and was later renamed TRC Capital Corporation in 2018 before changing to its current name in 2019.
Travere Therapeutics focuses on developing treatments for chronic kidney disease, a group of complex and progressive conditions that damage the kidneys over time, leading to a range of health problems. The company has several drugs in its pipeline aimed at treating various forms of chronic kidney disease and other rare disorders.
One of the company's key products is called JYNARQUE' (tolvaptan), a treatment for adult patients with autosomal dominant polycystic kidney disease (ADPKD). ADPKD is a genetic disorder that causes cysts to develop and enlarge in the kidneys, resulting in a range of complications including kidney failure, high blood pressure, and liver cysts. JYNARQUE' is the first FDA-approved treatment for ADPKD and works by decreasing the rate of kidney enlargement and disease progression.
Another product in Travere Therapeutics' pipeline is sparsentan, an investigational drug currently in Phase 3 clinical trials for the treatment of focal segmental glomerulosclerosis (FSGS) and IgA nephropathy (IgAN). FSGS and IgAN are two other types of chronic kidney disease that can lead to kidney failure if left untreated.
Travere Therapeutics also has a robust research and development program focused on the development of treatments for other rare and complex diseases. They have partnerships with other pharmaceutical companies and academic institutions to develop new therapies and bring them to market.
In addition to its drug development efforts, Travere Therapeutics is committed to working with patient advocacy groups to raise awareness about rare diseases and improve patient outcomes. The company also has a patient support program that provides assistance to patients who are prescribed its drugs, including financial assistance and access to educational resources.
Overall, Travere Therapeutics is a leading pharmaceutical company specializing in the development of treatments for rare and complex diseases, particularly chronic kidney disease. With an active pipeline of drug candidates and a commitment to patient advocacy, Travere Therapeutics is poised to make a significant impact on the healthcare industry.
Company Address: 3611 Valley Centre Drive San Diego 92130 CA
Company Phone Number: 969-7879 Stock Exchange / Ticker: NASDAQ TVTX
| TVTX is expected to report next financial results on October 26, 2023. |
|
|
|
|
|
|
|
|
| Stock Performances by Major Competitors |
|
|
|
|
Immuron Limited
In the financial fourth quarter of 2023, Immuron Limited, a major pharmaceutical preparations company, reported its financial results, which revealed a decrease in revenue and widened net loss. These figures mark a notable change compared to the corresponding financial reporting period from the previous year. This article aims to examine the context behind Immuron Limited's financial results, including its stock performance and implications for investors.
Financial Results:
Immuron Limited disclosed a revenue of $1.480365 million in the financial fourth quarter of 2023 after experiencing a net loss of $-3.787 million. These figures signify a departure from balanced books in the corresponding period a year earlier. Additionally, in the financial year 2023, the company announced a loss of $-3.79 million alongside a revenue of $1.48 million. In comparison to the prior financial year, the net loss per share has widened from $-1.25 to $-1.66, indicating a financial decline. However, it is important to note that the net loss remained unchanged from $0.00 million a year earlier.
|
|
Procyon Corporation
Procyon Corporation recently released their financial results for the fourth quarter of the 2023 earnings season. While the company reported unaltered earnings per share (EPS), a decline in revenue and other key indicators raises concerns about the company's future performance. This article aims to interpret the financial results and discuss their potential impact on Procyon Corporation going forward.
1. Earnings per Share (EPS) and Revenue Performance:
Procyon Corporation maintained an EPS of $0.00 in the fourth quarter, suggesting stability in their profitability. However, the company experienced a modest revenue decline of -0.589% year-on-year, amounting to $1.20 million. This decline sets Procyon apart from the rest of the Major Pharmaceutical Preparations industry, which recorded a revenue improvement during the same period.
|
|
Innovation Pharmaceuticals Inc
Innovation Pharmaceuticals Inc, a pharmaceutical company, recently announced its financial results for the fiscal year ending June 30, 2023. During this period, the company achieved a break-even point of $0.00 per share, which was the same as the previous year and the previous quarter.
However, the company did not generate any revenue during this quarter, remaining at $0.00 million, the same as the previous year and quarter. This indicates that there was no growth in the company's revenue during this period.
Additionally, Innovation Pharmaceuticals Inc reported a net shortfall of $-0.681 million for the fiscal year ending June 30, 2023. This is a significant improvement compared to the deficit of $-1.626 million reported in the same quarter a year ago. Although still in a shortfall, the company has managed to reduce its losses, which may indicate positive efforts in managing their expenses.
|
|
Palatin Technologies Inc
Financial News Report:
Palatin Technologies Inc Reports Strong Revenue Growth in Q4 2023, Despite Stock Deficit
Palatin Technologies Inc (PTN) has announced a substantial revenue advancement of 109.038% year on year to $1.76 million in the fourth quarter of 2023. However, the company posted a deficit per stock at $-0.98. Despite the stock deficit, PTN's revenue experienced significant growth compared to its peers in the Major Pharmaceutical Preparations industry. Most corporations in this industry saw an average revenue advance of 3.04% during the same period.
In comparison to the preceding reporting period, PTN's revenue surged by 47.359% from $1.20 million and the deficit improved from $0.00 per share. This strong revenue growth indicates a positive trend for Palatin Technologies Inc.
|
|
Ibio Inc
In the aftermath of Ibio Inc's recently released fourth-quarter earnings report, the company appears to be grappling with mounting losses and a steep decline in its share value. The financial results for the quarter ended in 2023 revealed a concerning trend of escalating losses for the biotechnology firm.
Earnings Overview:
During the fourth quarter of the 2023 earnings season, Ibio Inc reported a significant increase in its loss per share compared to the same period in the prior year. The loss per share surged from $-0.10 a year ago to $-0.97, representing a substantial deterioration. Additionally, the company witnessed a sequential increase in losses, reaching $-0.55 per share from the previous financial reporting period.
|
| Per Share |
Current |
| Earnings (TTM) |
-4.47 $ |
| Revenues (TTM) |
2.97 $
|
| Cash Flow (TTM) |
- |
| Cash |
6.46 $
|
| Book Value |
1.53 $
|
| Dividend (TTM) |
0 $ |
|
|
| Per Share |
|
| Earnings (TTM) |
-4.47 $
|
| Revenues (TTM) |
2.97 $ |
| Cash Flow (TTM) |
- |
| Cash |
6.46 $
|
| Book Value |
1.53 $ |
| Dividend (TTM) |
0 $ |
|
|
|
|
